Desmoglein reducer
A Marsh mallow extract-based desmoglein reducing agent addresses the inadequacies of existing methods by reducing desmoglein 1, improving skin brightness and softness, and preventing stratum corneum exfoliation, while aiding medicinal ingredient penetration.
Patent Information
- Application Number
- JP2020088903
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-05-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2040-05-21
AI Technical Summary
Existing methods for reducing desmoglein proteins, particularly desmoglein 1, are inadequate in effectively addressing skin conditions such as sensitive skin, skin brightness, and stratum corneum exfoliation.
A desmoglein reducing agent containing an extract of Marsh mallow (Athaea officinalis) is used to suppress intercellular adhesion of human epidermal keratinocytes, thereby reducing desmoglein 1 and improving skin conditions.
The agent effectively reduces desmoglein 1, leading to improved skin brightness, softness, and reduced stratum corneum exfoliation, enhancing the penetration of medicinal ingredients and providing a cosmetic or pharmaceutical solution for sensitive skin.
Smart Images

Figure 0007589413000002 
Figure 0007589413000003 
Figure 0007589413000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for reducing desmoglein. [Background technology]
[0002] Increased levels of desmosomal proteins are known to be one of the causes of deterioration of skin conditions, such as rough skin and peeling of the stratum corneum caused by sunburn or dryness. As a method for controlling the amount of desmosomal proteins, a method has been reported in which decomposition of desmosomal proteins accumulated in the stratum corneum with proteases is used to improve acne, dandruff, and desquamation (Patent Document 1).
[0003] Among desmosomal proteins, desmoglein in particular is known to be involved in adhesion between epidermal cells and between keratinocytes (Patent Documents 2-4).
[0004] As a prior art, Patent Document 2 reports an agent for reducing desmoglein in stratum corneum cells, which contains astaxanthin. Furthermore, Patent Document 4 reports an orally administered agent for inhibiting intercellular adhesion in the skin, which contains licorice extract as an active ingredient.
[0005] Incidentally, Patent Documents 5 and 6 report that an extract of marsh mallow (Athaea officinalis) has the effect of preventing and improving gray hair, and that tiliroside, a component of marsh mallow, has the effect of promoting fat metabolism. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Special Publication No. 7-505383 [Patent Document 2] JP 2016-37501 A [Patent Document 3] Patent No. 4002635 [Patent Document 4] Patent No. 4197194 [Patent Document 5] JP 2016-210755 A [Patent Document 6] JP 2007-176858 A Summary of the Invention [Problem to be solved by the invention]
[0007] In view of the above-mentioned prior art, an object of the present invention is to provide a novel technique for reducing desmograins.
[0008] As a result of extensive research, the present inventors have found that an extract of marsh mallow (Athaea officinalis) has a desmoglein-reducing effect, and have thus completed the present invention. [Means for solving the problem]
[0009] The present invention, which solves the above problems, provides a desmoglein-reducing agent containing an extract of marsh mallow (Athaea officinalis) as an active ingredient. In this specification, the concept of "reduction of desmoglein" includes both a reduction in desmoglein and inhibition of an increase in desmoglein.
[0010] In a preferred form of the invention, the active ingredient is an extract of the roots of Marsh mallow (Athaea officinalis).
[0011] In a preferred embodiment of the present invention, the desmoglein-reducing agent is used for inhibiting intercellular adhesion of human epidermal keratinocytes.
[0012] In a preferred embodiment of the present invention, the desmoglein-reducing agent of the present invention is used for reducing desmoglein 1. Desmoglein 1 is mainly present in the skin. Therefore, the desmoglein-reducing agent of the present invention, which has the effect of reducing desmoglein 1, can more efficiently prevent or improve the deterioration of skin conditions.
[0013] In a preferred embodiment of the present invention, the desmoglein reducing agent is used for improving and / or preventing sensitive skin.
[0014] In a preferred embodiment of the present invention, the desmoglein reducing agent is used to improve skin brightness.
[0015] In a preferred embodiment of the present invention, the desmoglein reducing agent is used to improve skin clarity.
[0016] In a preferred embodiment of the invention, the desmoglein reducing agent is used for softening the skin.
[0017] In a preferred embodiment of the present invention, the desmoglein-reducing agent is used to aid the penetration of medicinal ingredients into the skin.
[0018] In a preferred embodiment of the present invention, the desmoglein-reducing agent is used for preventing or improving stratum corneum desquamation.
[0019] Further, the present invention, which solves the above-mentioned problems, provides a composition for external application to the skin for inhibiting desmoglein, which contains the above-mentioned desmoglein reducer.
[0020] In a preferred embodiment of the present invention, the composition for external application to the skin for inhibiting desmoglein is a cosmetic preparation.
[0021] In a preferred embodiment of the present invention, the composition for external application to the skin for inhibiting desmoglein is a pharmaceutical product. Effect of the Invention
[0022] According to the present invention, a novel technique for reducing desmogleins can be provided. [Brief description of the drawings]
[0023] [Figure 1] FIG. 1 is a diagram showing test results of Example 1. [Diagram 2] 1 is a graph showing the test results of Example 1. [Diagram 3] 1 is a graph showing the measurement results of L* value in Example 2. [Figure 4] 1 is a graph showing the measurement results of a* value in Example 2. [Diagram 5] 1 is a graph showing the measurement results of b* value in Example 2. [Figure 6] 1 is a graph showing the results of hardness measurements in Example 2. [Figure 7] 1 is a graph showing the measurement results of the amount of desmoglein 1 in Example 2. [Figure 8] FIG. 1 is a diagram (representative) showing the measurement results of the amount of desmoglein 1 in Example 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] The desmoglein reducing agent of the present invention contains an extract of marsh mallow (Athaea officinalis, hereinafter simply referred to as marsh mallow) as an active ingredient. In particular, the desmoglein reducing agent of the present invention preferably contains an extract of the roots of Marshmallow as an active ingredient.
[0025] The marshmallow extract can be purchased and used from a commercially available marshmallow extract sold by a company that handles plant raw materials.
[0026] Also, a marshmallow extract can be produced by extracting wild or cultivated marshmallow. It is also preferred to prepare an extract of Marshmallow by extracting the roots of Marshmallow.
[0027] When extracting marshmallow, it is preferable to previously process the roots of marshmallow by crushing or cutting them into small pieces so as to improve the extraction efficiency.
[0028] The extract can be obtained, for example, by the following method. 1 to 30 parts by mass of a solvent is added to 1 part by mass of marshmallow root or its dried product, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed as desired, and then the solvent is removed by concentrating under reduced pressure or the like. The desired extract can then be obtained by fractionation and purification using column chromatography filled with silica gel or ion exchange resin.
[0029] Suitable examples of the extraction solvent include one or more selected from the group consisting of water, alcohols such as ethanol, propanediol, glycerin, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butylene glycol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. As the extraction solvent, alcohols are particularly preferred, and among these, propanediol and glycerin are preferred.
[0030] The content of the marshmallow extract in the desmoglein-reducing agent of the present invention is preferably 0.02 mass % or more, more preferably 0.05 mass % or more, even more preferably 0.08 mass % or more, and particularly preferably 0.1 mass % or more. The content of the extract of marshmallow is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.
[0031] The desmoglein-reducing agent of the present invention preferably targets desmoglein 1 for reduction.
[0032] The desmoglein-reducing agent of the present invention is preferably used for improving and / or preventing sensitive skin. Here, in this specification, "sensitive skin" refers to a skin type with reduced resistance (reduced skin irritation value) to external stimuli (dryness, ultraviolet rays, application of chemical compounds).
[0033] More specifically, "sensitive skin" in this specification refers to the skin types listed in (1) and / or (2).
[0034] (1) "Skin that is prone to skin problems due to reactions to topical medicines, cosmetics, plants, ultraviolet rays, metals, etc. Also, skin that is hypersensitive to allergens (pollen, fragrances, etc.) and irritants (alcohol, etc.)." (2) "Skin that is temporarily more susceptible to skin problems due to lack of sleep, overwork, menstruation, seasonal changes, mental stress, etc."
[0035] Additionally, in this specification, "for the improvement and / or prevention of sensitive skin" refers to the improvement of skin quality with reduced resistance to external stimuli (reduced skin irritation threshold) and / or the prevention of reduced resistance to external stimuli in skin quality (reduced skin irritation threshold).
[0036] In addition, the desmoglein-reducing agent of the present invention is preferably used for inhibiting intercellular adhesion of human epidermal keratinocytes. In this specification, the term "intercellular adhesion" refers to abnormalities in the adhesive function of the stratum corneum (progression of stratification of the stratum corneum due to increased cell adhesion) caused by an increase in desmosomal proteins (a group of proteins including desmoglein) (see Patent Nos. 4197194 and 4002635 for details). In addition, in this specification, the concept of "inhibiting intercellular adhesion" includes both prevention and improvement of intercellular adhesion.
[0037] Here, by inhibiting intercellular adhesion of human epidermal keratinocytes, stratification of the stratum corneum is inhibited, and an effect of inhibiting stratum corneum desquamation can be obtained. In other words, the desmoglein-reducing agent of the present invention can be used to prevent or improve stratum corneum desquamation. In this specification, the term "stratum corneum delamination" refers to the peeling off of the stratum corneum from the skin surface in a multi-layered state. Whether or not the skin is in a state where stratum corneum delamination can be confirmed by collecting the stratum corneum by tape stripping and staining and observing the collected stratum corneum.
[0038] Furthermore, as shown in the Examples described below, desmoglein 1 is present in large amounts in areas of the skin with low brightness, and it is believed that the decrease in skin brightness is due to stratification of the stratum corneum. In view of the above findings, by reducing desmoglein with the active ingredient of the present invention, it is possible to obtain an effect of improving skin brightness. That is, the active ingredient of the present invention can also be used as a skin lightening agent. In this specification, "improving skin brightness" refers to reducing the difference in brightness between skin in a normal state and skin whose brightness has been reduced due to the excess of desmoglein.
[0039] Furthermore, as shown in the examples described below, the desmoglein-reducing agent of the present invention can provide a skin condition with a more transparent appearance. In other words, the active ingredient of the present invention can also be used as an agent for improving skin transparency.
[0040] Furthermore, as shown in the Examples described below, desmoglein 1 is present in large amounts in areas of high skin hardness, and it is believed that the cause of skin hardness is the stratification of the stratum corneum. Based on the above findings, the effect of softening the skin can be obtained by reducing desmoglein, that is, the active ingredient of the present invention can also be used as a skin softener.
[0041] Here, by softening the skin, other medicinal ingredients can penetrate more efficiently, so by reducing desmoglein with the desmoglein reducer of the present invention, it is possible to obtain the effect of allowing medicinal ingredients such as whitening agents to penetrate the skin more efficiently. That is, the active ingredient of the present invention is preferably used as a whitening ingredient penetration aid for use in combination with a whitening agent.
[0042] In particular, the desmoglein-reducing agent of the present invention is preferably used as a whitening ingredient penetration aid for use in combination with a whitening agent.
[0043] The desmoglein-reducing agent of the present invention can be a composition for external application to the skin or a composition for oral administration. In particular, the desmoglein-reducing agent of the present invention is preferably in the form of a composition for external use on the skin.
[0044] Suitable examples of skin external compositions include cosmetics and pharmaceuticals.
[0045] Among these, it is preferable that the composition is in the form of a cosmetic preparation that can be used continuously, for example, a lotion, milky lotion, beauty essence, cream, gel, sun care product, or the like.
[0046] The content of the extract of Marshmallow in the composition for external use on skin is 0.02% by mass or more, preferably 0.05% by mass or more, and more preferably 0.1% by mass or more. The content of the extract of marsh mallow (Athaea officinalis) in the composition for external use on skin is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.
[0047] When the composition is provided in the form of a skin external composition, its composition is not particularly limited, and it can contain any optional ingredient that is usually used, as long as it does not impair the effect of the present invention.Such optional ingredients include, for example, oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ivotaro wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum, micelle, and the like. Hydrocarbons such as locrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, sebacic acid, and the like; synthetic ester oils such as di-2-ethylhexyl phosphate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate, and other oils; fatty acid soaps (sodium laurate, sodium palmitate, etc.); anionic surfactants such as potassium lauryl sulfate, alkyl sulfate triethanolamine ether; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide; amphoteric surfactants such as imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfo betaine, etc.), and acyl methyl taurine;Sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitol fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic (registered trademark) types, Preferred examples of the surfactants include nonionic surfactants such as POE·POP alkyl ethers (POE·POP 2-decyltetradecyl ether, etc.), tetronics, POE castor oil / hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, and alkyl glucosides; polyhydric alcohols such as polyethylene glycol, glycerin, erythritol, sorbitol, maltitol, propylene glycol, and 2,4-hexanediol; moisturizing ingredients such as sodium pyrrolidone carboxylate, lactic acid, and sodium lactate; para-aminobenzoic acid-based ultraviolet absorbers; anthranilic acid-based ultraviolet absorbers; salicylic acid-based ultraviolet absorbers; cinnamic acid-based ultraviolet absorbers; benzophenone-based ultraviolet absorbers; sugar-based ultraviolet absorbers; and ultraviolet absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.
[0048] When the composition is prepared as an oral composition, it is preferable to prepare a food composition containing the active ingredient of the present invention. Specifically, the composition may be in the form of a supplement having the dosage form of a general food, tablet, granule, drink, or the like.
[0049] Here, the content and content ratio of the marshmallow extract in the oral composition can be applied mutatis mutandis to the description of the preferred embodiment of the topical skin composition described above.
[0050] When the composition is prepared as an oral composition, any optional ingredient may be appropriately blended within a range that does not impair the effects of the present invention.
[0051] The present invention also relates to a method for preparing Desmoglace on the skin, which comprises applying an extract of Marshmallow to the skin. According to the present invention, sensitive skin can be prevented or improved by applying an extract of Marshmallow to the skin.
[0052] Here, the method for preparing desmoglein on the skin according to the present invention is a non-therapeutic method, preferably a cosmetic method, more preferably a cosmetic method for the skin. EXAMPLES
[0053] [Example 1] Measurement of desmoglein reduction effect Below, the desmoglein-reducing ability of the extract of Marshmallow root was examined.
[0054] <Preparation process of stratum corneum cell samples> The stratum corneum was collected from the outer side of a human forearm using cellophane tape and transferred to a slide glass ("MAS Coat", Matsunami Glass Industry Co., Ltd.), and the slide glass was immersed in xylene overnight. Next, the slide glass was washed twice with xylene for 10 minutes each, and then washed with PBS to prepare a keratinocyte sample.
[0055] <Preparation of test samples and target samples> A test sample was obtained by diluting an extract of marshmallow roots (manufactured by Jurlique) with PBS to a concentration of 0.25% by mass.
[0056] <Preparation of measurement samples> The stratum corneum cells were immersed in the above-mentioned test sample overnight to obtain a measurement sample for Example 1. As a reference example (control), stratum corneum cells that were not immersed in the above-mentioned test samples were prepared.
[0057] <Immunostaining test> The measurement sample was washed with PBS and then incubated in 4% PFA-phosphate buffer at room temperature for 15 minutes. After incubation, the measurement sample was washed with PBS and incubated in 20% Block Ace (DS Biopharma Medical) aqueous solution at room temperature for 1 hour. Thereafter, a primary antibody (Anti-Desmoglein 1, Mouse-Mono) was added, and the sections were incubated in a humidified box at room temperature for 2 hours.
[0058] Each measurement sample was washed three times with PBS for 5 minutes each, and then a secondary antibody (Allexa Fluor@488 Goat Anti-mouse IgG) was added and incubated in a humidified box at room temperature for 1 hour. Each measurement sample was washed three times with PBS for 5 minutes each, washed twice with distilled water, and then mounted using Fluoromout-G (manufactured by Southern Biotech). After that, the measurement samples were photographed using a confocal laser microscope to capture analytical images, and the fluorescence (staining) was confirmed. The results are shown in Figure 1.
[0059] Additionally, the area of the fluorescent (stained) portion of the measurement sample in Example 1 was calculated based on the area of the fluorescent (stained) portion of the control being 100%. The results are shown in Table 1 and FIG.
[0060] [Table 1]
[0061] As shown in Figures 1 and 2, it was found that the expression level of desmoglein 1 was suppressed in the measurement sample (Example 1) to which marshmallow extract was added, compared to the sample (Reference Example) to which marshmallow extract was not added. These results demonstrated that marshmallow extract has the effect of suppressing the amount of desmoglein 1.
[0062] [Example 2] Relationship between skin brightness and / or skin hardness and the amount of desmoglein 1 Below are test results that support the relationship between differences in skin brightness and the amount of desmoglein 1 present, as well as the relationship between the amount of desmoglein 1 present and skin hardness.
[0063] (1) Subjects and measurement sites In this example, 20 women aged between 40 and 52 years old were used as subjects. In this embodiment, the areas on the subject's face where a decrease in brightness was visually confirmed (blackish areas, see area A in Figure 8) and an area in a normal state (see area B in Figure 8) were selected as measurement areas.
[0064] (2) Measurement (2-1)L * Value, a * Value, b * Value Measurement By placing a spectrophotometer on the above measurement sites and measuring each site five times, L * Value, a * Value, b * The values were measured. The results are shown in FIGS.
[0065] L * Regarding the value, the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) showed significantly lower values than the areas in the normal state (see area B in Figure 8). In other words, it was confirmed that the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) were darker than the areas in the normal state (see area B in Figure 8).
[0066] a *Regarding the value, the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) showed significantly higher values than the areas in the normal state (see area B in Figure 8). In other words, it was confirmed that the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) were redder than the areas in the normal state (see area B in Figure 8).
[0067] b * Regarding the value, the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) showed significantly higher values than the areas in the normal state (see area B in Figure 8). In other words, it was confirmed that the areas where it was confirmed by visual inspection that the brightness had decreased (the dark areas, see area A in Figure 8) were more yellowish than the areas in the normal state (see area B in Figure 8).
[0068] (2-2) Hardness measurement The hardness was measured by pressing an indenter against each measurement site used in the above test (2-1) and measuring five times each. The results are shown in Figure 6.
[0069] Regarding hardness, the areas where reduced brightness was visually confirmed (blackish areas, see area A in Figure 8) showed significantly lower values than the areas in a normal state (see area B in Figure 8). In other words, the areas where reduced brightness was visually confirmed (blackish areas, see area A in Figure 8) were confirmed to be harder than the areas in a normal state (see area B in Figure 8).
[0070] (2-3) Desmoglein 1 (Dsg1) staining Corneal stratum corneum cells were collected from each measurement site used in the above tests (2-1) and (2-2) by tape stripping and attached to a slide glass.
[0071] The slide glass to which the keratinocytes were attached was immersed in xylene overnight. After immersion, the specimen was washed and air-dried, and then left to stand in 4% paraformaldehyde-phosphate buffer at room temperature for 15 minutes.
[0072] After 15 minutes, the stratum corneum cells were washed with PBS and immersed in a 0.5% TritonX (Nacalai Tesque) / PBS solution at room temperature for 5 minutes.
[0073] After immersion, the sample was washed and then allowed to stand in an aqueous solution of Block Ace (DS Biopharma Medical UK-B80) at room temperature for 1 hour.
[0074] After standing, the plate was framed with Liquid Blocker (manufactured by Daido Sangyo Co., Ltd.), a primary antibody was added, and the plate was left standing in a humidified box at room temperature for 2 hours. The primary antibody used was Anti Desmoglein 1, Mouse Mono (Dsg1 P23) Progen, 651110 stock solution (IgG concentration: 10-15 g / mL).
[0075] After standing, the sections were washed with PBS, a secondary antibody was added, and the sections were left standing in a humidified box at room temperature for 1 hour. The secondary antibody used was Allexa Fluor@488 Goat Anti mouse IgG Invitrogen, A 11001, diluted 200-fold in PBS.
[0076] After standing, the plate was washed, sealed with Fluoromout-G (manufactured by Southern Biotech), and dried at room temperature for 30 minutes.
[0077] After drying, the cover glass was fixed with nail polish, allowed to dry, and then (photographed) observed under a confocal laser microscope (Nikon A1) at ×20. The results are shown in Figure 7.
[0078] Regarding the amount of desmoglein 1 (Dsg1), the areas where a decrease in brightness was visually confirmed (the dark areas, see area A in Figure 8) showed significantly higher values than the areas in a normal state (see area B in Figure 8). In other words, it was confirmed that the areas where a decrease in brightness was visually confirmed (the dark areas, see area A in Figure 8) had a higher amount of desmoglein 1 (Dsg1) than the areas in a normal state (see area B in Figure 8).
[0079] (3) Discussion As shown in Figures 3 to 5 and 7, it was found that desmoglein 1 was present in large amounts in areas of the skin with low brightness. Here, the decrease in skin brightness is thought to be due to the dense layering of the stratum corneum (stratification of the stratum corneum) caused by the low pH of the skin and low activity of serine protease, which breaks down desmoglein 1.
[0080] As described above, the active ingredient of the present invention has the effect of reducing desmoglein. In view of the above findings, it has been found that the active ingredient of the present invention has the effect of improving skin brightness by reducing desmoglein 1.
[0081] As shown in Figures 6 to 7, it was found that areas with high skin hardness had a large amount of desmoglein 1. Here, the cause of skin hardness is thought to be the dense layering of the stratum corneum (stratification of the stratum corneum) due to the low pH of the skin and low activity of serine protease that breaks down desmoglein 1.
[0082] Based on the above findings, it was found that reducing desmoglein 1 can soften the skin. As described above, the active ingredient of the present invention has the effect of reducing desmoglein. In other words, it was found that the active ingredient of the present invention has a skin softening effect by reducing desmoglein 1. [Industrial Applicability]
[0083] The present invention can be applied to cosmetics.
Claims
1. A skin preparation for external application containing an extract of marsh mallow (Athaeea officinalis) as an active ingredient, for application to dark areas of the skin; In the darker areas of the skin, To soften the firmness of said skin, or To allow the medicinal ingredients to penetrate the skin efficiently A desmoglein reducer used in.
2. 2. The method of claim 1, wherein the extract is an extract of the roots of Marsh mallow (Athaea officinalis).
3. The desmoglein-reducing agent according to claim 1 or 2, for inhibiting intercellular adhesion of human epidermal keratinocytes.
4. The desmoglein reducing agent according to any one of claims 1 to 3, wherein the target for reduction is desmoglein 1.
5. The desmogrease according to any one of claims 1 to 4 for improving and / or preventing sensitive skin. In reducer.
6. A desmoglein reducing agent according to any one of claims 1 to 4 for improving skin brightness.
7. A desmoglein reducing agent according to any one of claims 1 to 4 for improving skin transparency.
8. A desmoglein reducing agent according to any one of claims 1 to 4 for softening the skin.
9. The desmoglein reducing agent according to any one of claims 1 to 4, for aiding the penetration of medicinal ingredients into the skin.
10. The desmoglein-reducing agent according to any one of claims 1 to 4, for improving and / or preventing stratum corneum desquamation.
11. A composition for external application to the skin for reducing desmoglein, comprising the desmoglein reducing agent according to any one of claims 1 to 4.
12. The composition for external application to the skin for reducing desmoglein according to claim 11, which is a cosmetic product.
13. The composition for external application to the skin for reducing desmoglein according to claim 11, which is a pharmaceutical product.
Citation Information
Patent Citations
Skin care method and composition
JP1995505383A
Skin care preparation
JP2003292432A
NF-kappaB ACTIVATION INHIBITOR
JP2005194246A
Fat metabolism promoter or antidiabetic
JP2007176858A
Cosmetic
JP2010241762A
